Guardant Health, Inc. (GH) News
Filter GH News Items
GH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GH News Highlights
- For GH, its 30 day story count is now at 10.
- Over the past 28 days, the trend for GH's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about GH are ALTO and TOP.
Latest GH News From Around the Web
Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development ActivitiesLONDON & PALO ALTO, Calif., December 04, 2023--Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment. |
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detectionPALO ALTO, Calif., November 30, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual diseas |
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units ("RSUs") representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs were granted as inducements material to the employe |
Guardant Health to Appeal Federal District Court VerdictPALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington. |
Guardant Health launches Shield blood-based screening test for colorectal cancer in South KoreaGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. |
Guardant Health, Inc. (NASDAQ:GH) Q3 2023 Earnings Call TranscriptGuardant Health, Inc. (NASDAQ:GH) Q3 2023 Earnings Call Transcript November 6, 2023 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.93. Operator: Hello, everyone, and welcome to the Guardant Health Q3 2023 Earnings Call. My name is Thrisha, and I’ll be your operator today. [Operator Instructions] I will now hand you […] |
Q3 2023 Guardant Health Inc Earnings CallQ3 2023 Guardant Health Inc Earnings Call |
Guardant Health (GH) Reports Q3 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
Guardant Health Inc (GH) Reports 22% Revenue Growth for Q3 2023Company's clinical volume growth drives revenue increase and raises 2023 revenue guidance |
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue GuidancePALO ALTO, Calif., November 06, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. |